Tevogen Bio Holdings Inc. announced that it's ExacTcell platform was developed to harness the killing ability of naturally occurring cytotoxic T lymphocytes (CTLs), against viral and malignant targets. TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome. These cells were well tolerated in a completed proof of concept clinical trial in high-risk patients with acute COVID-19, with later stage studies planned in this area.

Tevogen plans to assess whether TVGN 489 cells can rapidly eliminate symptoms of Long Covid. Specific HLA types may be associated with more or less protection against a particular infection. Prior to launching the Long COVID clinical trial, Tevogen seeks to address whether Long COVID occurs more commonly with certain HLA types and less commonly with others, or whether Long COVID occurs randomly in the population regardless of HLA.

This effort will help Tevogen generate CTL products recognizing the HLA types that are most commonly associated with Long Covid, if a relationship between Long Covid and HLA type is identified, with the goal of allowing a Long COVID treatment trial to be designed and completed expeditiously.